Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid...
3 contributing indexes 4 score components composite score.
Canonical asset packet first: fundamentals, macro index exposure, entry value, and active narrative alignment. Driver rows link back to the public index that moved the score.
| Index | Driver | Reason | Weight | Condition | Contribution | As Of |
|---|---|---|---|---|---|---|
| RACI | Robotics & Automation Capex Index | research activity | 7% | research activity — tailwind Moderate signal—/100Tailwind +0.53σ | +0.041 | 2026-05-22 |
| BPHI | Biotech & Pharma Health Index | gene editing innovation | 17% | gene editing innovation — tailwind Near normal—/100Tailwind +0.13σ | +0.031 | 2026-05-22 |
| RQRI | Risk-Quality Rotation Index | risk appetite | 3% | risk appetite — tailwind Moderate signal—/100Tailwind +1.30σ | +0.028 | 2026-05-22 |
